NasdaqGS - Nasdaq Real Time Price USD

Vor Biopharma Inc. (VOR)

Compare
0.8398 +0.0414 (+5.19%)
At close: October 31 at 4:00 PM EDT
0.8700 +0.03 (+3.60%)
Pre-Market: 9:21 AM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
124,801.0000
126,036.0000
93,418.0000
69,018.0000
43,366.0000
Operating Income
-124,801.0000
-126,036.0000
-93,418.0000
-69,018.0000
-43,366.0000
Net Non Operating Interest Income Expense
6,707.0000
8,173.0000
1,324.0000
119.0000
29.0000
Pretax Income
-118,094.0000
-117,863.0000
-92,094.0000
-68,899.0000
-43,337.0000
Net Income Common Stockholders
-118,094.0000
-117,863.0000
-92,094.0000
-70,127.0000
-49,262.0000
Diluted NI Available to Com Stockholders
-118,094.0000
-117,863.0000
-92,094.0000
-70,127.0000
-49,262.0000
Basic EPS
-1.73
-1.75
-2.33
-2.10
-1.42
Diluted EPS
-1.73
-1.75
-2.33
-2.10
-1.42
Basic Average Shares
67,948.7340
67,191.9730
39,551.4200
33,433.2140
34,641.3600
Diluted Average Shares
67,948.7340
67,191.9730
39,551.4200
33,433.2140
34,641.3600
Total Operating Income as Reported
-124,801.0000
-126,036.0000
-93,418.0000
-69,018.0000
-43,366.0000
Total Expenses
124,801.0000
126,036.0000
93,418.0000
69,018.0000
43,366.0000
Net Income from Continuing & Discontinued Operation
-118,094.0000
-117,863.0000
-92,094.0000
-68,899.0000
-43,337.0000
Normalized Income
-118,094.0000
-117,863.0000
-92,094.0000
-68,899.0000
-43,337.0000
Interest Income
6,707.0000
8,173.0000
1,324.0000
119.0000
29.0000
Net Interest Income
6,707.0000
8,173.0000
1,324.0000
119.0000
29.0000
EBIT
-124,801.0000
-126,036.0000
-93,418.0000
-69,018.0000
-43,366.0000
EBITDA
-121,204.0000
-122,544.0000
-90,893.0000
-67,584.0000
-42,761.0000
Reconciled Depreciation
3,597.0000
3,492.0000
2,525.0000
1,434.0000
605.0000
Net Income from Continuing Operation Net Minority Interest
-118,094.0000
-117,863.0000
-92,094.0000
-68,899.0000
-43,337.0000
Normalized EBITDA
-121,204.0000
-122,544.0000
-90,893.0000
-67,584.0000
-42,761.0000
12/31/2020 - 2/5/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers